title: Individualized tumor response testing profile has a prognostic value in childhood acute leukemias: multicenter non-interventional long-term follow-up study.
abstract: A total number of 817 children with acute lymphoblastic leukemia (ALL) and 181 with acute myeloblastic leukemia (AML) were assessed for individualized tumor response testing (ITRT) profile as a prognostic factor in long-term follow-up. For each patient, ITRT, initial response to therapy and long-term outcome were assessed. In initial ALL, an impact on long-term response was shown in ITRT for 13 drugs, while in initial AML only for cytarabine. For patients with ALL, a combined five-drug ITRT profile for prednisolone, l-asparaginase, vincristine, cytarabine and daunorubicin or doxorubicin had predictive value for probability of disease-free survival (pDFS) in univariate analysis, whereas in multivariate analysis, bone marrow response by day 33 was the only prognostic factor. For patients with AML, no factor had prognostic value for pDFS in univariate analysis, while ITRT to cytarabine almost reached significance. In conclusion, ITRT can possibly be regarded as a risk factor in childhood acute leukemias.
authors.affiliation: Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. magda_piatkowska@o2.pl
authors.forename: Magdalena
authors.initials: M
authors.lastname: Piatkowska
authors.forename: Jan
authors.initials: J
authors.lastname: Styczynski
authors.forename: Beata
authors.initials: B
authors.lastname: Kolodziej
authors.forename: Beata
authors.initials: B
authors.lastname: Kurylo-Rafinska
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Kubicka
authors.forename: Monika
authors.initials: M
authors.lastname: Pogorzala
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Czyzewski
authors.forename: Robert
authors.initials: R
authors.lastname: Debski
authors.forename: Michal
authors.initials: M
authors.lastname: Matysiak
authors.forename: Iwona
authors.initials: I
authors.lastname: Malinowska
authors.forename: Walentyna
authors.initials: W
authors.lastname: Balwierz
authors.forename: Edyta
authors.initials: E
authors.lastname: Juraszewska
authors.forename: Jacek
authors.initials: J
authors.lastname: Wachowiak
authors.forename: Benigna
authors.initials: B
authors.lastname: Konatkowska
authors.forename: Maria
authors.initials: M
authors.lastname: Wieczorek
authors.forename: Igor
authors.initials: I
authors.lastname: Olejnik
authors.forename: Maryna
authors.initials: M
authors.lastname: Krawczuk-Rybak
authors.forename: Marta
authors.initials: M
authors.lastname: Kuzmicz
authors.forename: Jerzy
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: Maria Jolanta
authors.initials: MJ
authors.lastname: Stefaniak
authors.forename: Wanda
authors.initials: W
authors.lastname: Badowska
authors.forename: Tomasz
authors.initials: T
authors.lastname: Szczepanski
authors.forename: Renata
authors.initials: R
authors.lastname: Tomaszewska
authors.forename: Elżbieta
authors.initials: E
authors.lastname: Adamkiewicz-Drozynska
authors.forename: Lucyna
authors.initials: L
authors.lastname: Maciejka-Kapuscinska
authors.forename: Grazyna
authors.initials: G
authors.lastname: Sobol
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Mizia-Malarz
authors.forename: Mariusz
authors.initials: M
authors.lastname: Wysocki
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D019008:Drug Resistance, Neoplasm; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000188:drug therapy*; D011379:Prognosis; D012307:Risk Factors; D016896:Treatment Outcome; D055815:Young Adult